Abstract Library

#4096 Co-production of patient information: A model for today’s practice

Introduction: According to the British Medical Association, good quality patient information is fundamental to effective, patient-centred, quality care. It rightly considers patients as partners in their care, “Co-production involves engaging groups of people who use healthcare services, in equal partnership; at the earliest stages of service design, development and evaluation. It acknowledges that people with ‘lived experience’ of a particular condition are often best placed to advise on what support and services will make a positive difference to their lives.” (NHS England) The re-introduction of a liver transplantation programme in the UK for selected patients with a Neuroendocrine Neoplasm offers new opportunities to improve survival and quality of life: good quality information is a key tool for informed consent.

Conference:

Presenting Author:

Authors: Jervis N, Ellis C, Smith S, Shah T, Lewis K,

Keywords: Liver Transplantation, Co-production, Patient Information, Lived Experience Contribution,

#3954 Comparison of transarterial embolisation (TAE) or chemoembolisation (TACE) using streptozotocin (STZ) and biomarker study in patients with metastatic neuroendocrine tumors (NET)

Introduction: We compared TACE and TAE in patients with pancreatic (pNET) or small-intestine NET (siNET) and explored the role of biomarkers related to alkylating agents (O6-methylguanine-methyltransferase [MGMT], alkylpurine–DNA–N-glycosylase [APNG]) or hypoxia (Carbonic anhydrase IX [CAIX]).

Conference:

Presenting Author: de Mestier L

Authors: Vedie A, Dioguardii Burgioo M, Matteini F, Akez M, Hentic O,

Keywords: transarterial embolization, chemoembolization, metastatic neuroendocrine tumor, biomarker,

#3864 Efficacy and safety of capecitabine and temozolomide (CAPTEM) in advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) – A systematic review and metanalysis

Introduction: Gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) are heterogeneous tumors, with multiple therapeutic options for advanced stages. The combination of capecitabine and temozolomide (CAPTEM) is increasingly used for advanced GEP-NEN, but evidence on results is sparse.

Conference:

Presenting Author: Tacelli M

Authors: Tacelli M, Massironi S, Gallo C, Bina N, Stornello C,

Keywords: chemotherapy, pfs, progression-free survival, adverse events,

#3857 The use of quantitative contrast-enhanced endoscopic ultrasound in the evaluation of pancreatic neuroendocrine tumors – Can we move from quality to quantity? A proof-of-concept study

Introduction: Contrast-enhanced EUS (CE-EUS) is a helpful tool for the diagnosis of pancreatic focal lesions, as pancreatic cancer (PC) and pancreatic neuroendocrine tumor (pNEN). The enhancement of the lesion after contrast medium injection is usually assessed qualitatively and arbitrarily by the endosonographer. Dedicated software has recently been developed to obtain an unbiased quantitative assessment using perfusion parameters.

Conference:

Presenting Author: Tacelli M

Authors: Tacelli M, Bina N, Capurso G, Zaccari P, Petrone M,

Keywords: CE-EUS, pNEN, artificial intelligence, pancreatic cancer, prediction,

#3643 Effect of resection timing as part of multidisciplinary treatment for pancreatic NEN liver metastases

Introduction: Liver metastases are treated by resection if radical resection is possible as a part of multidisciplinary treatment along with pharmacotherapy and TACE.

Conference:

Presenting Author:

Authors: Masui T, Nagai K, Anazawa T, Kasai Y, Yogo A,

Keywords: liver metastasis, multidisciplinary treatment,